BioGaia AB (publ)

BioGaia AB (publ) is a Swedish biotechnology and healthcare company specializing in the development, manufacturing, marketing, and sale of probiotic products based on patented Lactobacillus reuteri strains. These products target gut, oral, and immune health, with offerings segmented into Pediatrics, Adult Health, and Other categories. The Pediatrics segment includes drops, oral rehydration solutions, gut health tablets, and cultures for infant formula, while Adult Health provides gut health tablets, oral health lozenges, and cultures for dairy products. The company pioneered microbiome research over 35 years, investing about 11% of net sales in R&D to validate efficacy in applications like infant colic relief, diarrhea prevention, H. pylori eradication, gingivitis amelioration, and general illness prevention. Founded in 1990 and headquartered in Stockholm, BioGaia operates in over 100 countries through distribution partners and its own subsidiaries across EMEA, Americas, and APAC. With 225 employees, around 600 granted patents, and 270 published studies, it holds a leading position in the global probiotics market, emphasizing clinically proven health benefits and sustainability.